Literature DB >> 33004675

Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau.

Nabil F Darwich1, Jessica M Phan1, Boram Kim1, EunRan Suh2, John D Papatriantafyllou3, Lakshmi Changolkar2, Aivi T Nguyen1, Caroline M O'Rourke1, Zhuohao He2, Sílvia Porta2, Garrett S Gibbons2, Kelvin C Luk2, Sokratis G Papageorgiou4, Murray Grossman5, Lauren Massimo5, David J Irwin5, Corey T McMillan5, Ilya M Nasrallah6, Camilo Toro7, Geoffrey K Aguirre5, Vivianna M Van Deerlin2, Edward B Lee8.   

Abstract

Neurodegeneration in Alzheimer's disease (AD) is closely associated with the accumulation of pathologic tau aggregates in the form of neurofibrillary tangles. We found that a p.Asp395Gly mutation in VCP (valosin-containing protein) was associated with dementia characterized neuropathologically by neuronal vacuoles and neurofibrillary tangles. Moreover, VCP appeared to exhibit tau disaggregase activity in vitro, which was impaired by the p.Asp395Gly mutation. Additionally, intracerebral microinjection of pathologic tau led to increased tau aggregates in mice in which p.Asp395Gly VCP mice was knocked in, as compared with injected wild-type mice. These findings suggest that p.Asp395Gly VCP is an autosomal-dominant genetic mutation associated with neurofibrillary degeneration in part owing to reduced tau disaggregation, raising the possibility that VCP may represent a therapeutic target for the treatment of AD.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33004675      PMCID: PMC7818661          DOI: 10.1126/science.aay8826

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  34 in total

1.  Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration.

Authors:  J Paul Taylor
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

2.  Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.

Authors:  Kelvin C Luk; Victoria Kehm; Jenna Carroll; Bin Zhang; Patrick O'Brien; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

3.  An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex.

Authors:  Ye Zhang; Kenian Chen; Steven A Sloan; Mariko L Bennett; Anja R Scholze; Sean O'Keeffe; Hemali P Phatnani; Paolo Guarnieri; Christine Caneda; Nadine Ruderisch; Shuyun Deng; Shane A Liddelow; Chaolin Zhang; Richard Daneman; Tom Maniatis; Ben A Barres; Jian Qian Wu
Journal:  J Neurosci       Date:  2014-09-03       Impact factor: 6.167

4.  Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP•NPLOC4•UFD1L is enhanced by a mutation that causes multisystem proteinopathy.

Authors:  Emily E Blythe; Kristine C Olson; Vincent Chau; Raymond J Deshaies
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-16       Impact factor: 11.205

5.  ATPase activity of p97-valosin-containing protein (VCP). D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity.

Authors:  Changcheng Song; Qing Wang; Chou-Chi H Li
Journal:  J Biol Chem       Date:  2002-11-20       Impact factor: 5.157

6.  Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation.

Authors:  Dalia Halawani; Andréa C LeBlanc; Isabelle Rouiller; Stephen W Michnick; Marc J Servant; Martin Latterich
Journal:  Mol Cell Biol       Date:  2009-06-08       Impact factor: 4.272

7.  Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies.

Authors:  Garrett S Gibbons; Rachel A Banks; Bumjin Kim; Lakshmi Changolkar; Dawn M Riddle; Susan N Leight; David J Irwin; John Q Trojanowski; Virginia M Y Lee
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

8.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

9.  Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.

Authors:  Jing L Guo; Sneha Narasimhan; Lakshmi Changolkar; Zhuohao He; Anna Stieber; Bin Zhang; Ronald J Gathagan; Michiyo Iba; Jennifer D McBride; John Q Trojanowski; Virginia M Y Lee
Journal:  J Exp Med       Date:  2016-10-17       Impact factor: 14.307

10.  Structure of the Cdc48 ATPase with its ubiquitin-binding cofactor Ufd1-Npl4.

Authors:  Nicholas O Bodnar; Kelly H Kim; Zhejian Ji; Thomas E Wales; Vladimir Svetlov; Evgeny Nudler; John R Engen; Thomas Walz; Tom A Rapoport
Journal:  Nat Struct Mol Biol       Date:  2018-07-02       Impact factor: 15.369

View more
  18 in total

1.  Therapeutic genetic variation revealed in diverse Hsp104 homologs.

Authors:  Katelyn Sweeney; Hanna Kim; Xiaohui Yan; Zachary M March; Laura M Castellano; Meredith E Jackrel; JiaBei Lin; Edward Chuang; Edward Gomes; Corey W Willicott; Karolina Michalska; Robert P Jedrzejczak; Andrzej Joachimiak; Kim A Caldwell; Guy A Caldwell; Ophir Shalem; James Shorter
Journal:  Elife       Date:  2020-12-15       Impact factor: 8.140

Review 2.  Multisystem Proteinopathy Due to VCP Mutations: A Review of Clinical Heterogeneity and Genetic Diagnosis.

Authors:  Gerald Pfeffer; Grace Lee; Carly S Pontifex; Roberto D Fanganiello; Allison Peck; Conrad C Weihl; Virginia Kimonis
Journal:  Genes (Basel)       Date:  2022-05-27       Impact factor: 4.141

Review 3.  The Cryo-EM Effect: Structural Biology of Neurodegenerative Disease Proteostasis Factors.

Authors:  Benjamin C Creekmore; Yi-Wei Chang; Edward B Lee
Journal:  J Neuropathol Exp Neurol       Date:  2021-06-04       Impact factor: 3.685

Review 4.  Combating deleterious phase transitions in neurodegenerative disease.

Authors:  April L Darling; James Shorter
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-02-05       Impact factor: 4.739

Review 5.  Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jessica Root; Paola Merino; Austin Nuckols; Michelle Johnson; Thomas Kukar
Journal:  Neurobiol Dis       Date:  2021-03-31       Impact factor: 7.046

6.  Classification of diseases with accumulation of Tau protein.

Authors:  Gabor G Kovacs; Bernardino Ghetti; Michel Goedert
Journal:  Neuropathol Appl Neurobiol       Date:  2022-02-09       Impact factor: 6.250

Review 7.  DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimer's, Related Tauopathies and Genetic Tauopathies.

Authors:  Geraldine Zimmer-Bensch; Hans Zempel
Journal:  Cells       Date:  2021-11-07       Impact factor: 6.600

8.  Tau immunotherapy is associated with glial responses in FTLD-tau.

Authors:  Boram Kim; Bailey Mikytuck; Eunran Suh; Garrett S Gibbons; Vivianna M Van Deerlin; Sanjeev N Vaishnavi; Meredith A Spindler; Lauren Massimo; Murray Grossman; John Q Trojanowski; David J Irwin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2021-05-05       Impact factor: 17.088

Review 9.  Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.

Authors:  Aiko Robert; Michael Schöll; Thomas Vogels
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

10.  Neuronal VCP loss of function recapitulates FTLD-TDP pathology.

Authors:  Abubakar Wani; Jiang Zhu; Jason D Ulrich; Abdallah Eteleeb; Andrew D Sauerbeck; Sydney J Reitz; Khalid Arhzaouy; Chiseko Ikenaga; Carla M Yuede; Sara K Pittman; Feng Wang; Shan Li; Bruno A Benitez; Carlos Cruchaga; Terrance T Kummer; Oscar Harari; Tsui-Fen Chou; Rolf Schröder; Christoph S Clemen; Conrad C Weihl
Journal:  Cell Rep       Date:  2021-07-20       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.